Search Medical Condition
Please enter condition
Please choose location

Ota-city, Japan Clinical Trials

A listing of Ota-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (355) clinical trials

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

The maximum study duration per patient will be approximately 41 weeks: an up to 14-week screening period (consisting of an up to 2-week screening phase and a 12-week run-in phase), a 26-week randomized treatment period, and a 3-day post-treatment safety follow-up period.

Phase

0.0 miles

Learn More »

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

This is a phase 3, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics of long-term administration of TAK-536 once daily for 52 weeks in pediatric patients aged 6 to less than 16 years with hypertension. The study consists of a 2-week Run-in Period, a 52-week Treatment Period (Treatment ...

Phase

0.0 miles

Learn More »

A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients

Subjects will receive 14 weeks of Gabapentin enacarbil or placebo.

Phase

0.0 miles

Learn More »

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

The total study duration per patient is expected to be up to 68 weeks that will consist of a 4-week run-in period, 52-week treatment period, and a 12-week posttreatment period.

Phase

0.0 miles

Learn More »

Long-term Study of Lemborexant in Insomnia Disorder

This is a long-term (approximately 1 year), multicenter, randomized, controlled, double-blind, parallel group study of two doses of lemborexant and placebo in approximately 900 male or female participants with insomnia disorder. Approximately 40% of participants will be age 65 years or older. The study will last a maximum of 60 ...

Phase

0.0 miles

Learn More »